{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:11:16Z","timestamp":1788466276151,"version":"build-2803163510"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Digestive tract cancers, including esophageal, gastric, and colorectal cancers, are the major cause of death among cancer patients worldwide due to the heterogeneity of cancer cells, which limits the effectiveness of traditional treatment methods. Immunotherapy represents a promising treatment strategy for improving the prognosis of patients with digestive tract cancers. However, the clinical application of this approach is limited by the absence of optimal targets. Cancer\/testis antigens are characterized by low or absent expression in normal tissues, but high expression in tumor tissues, making them an attractive target for antitumor immunotherapy. Recent preclinical trials have shown promising results for cancer\/testis antigen-targeted immunotherapy in digestive cancer. However, practical problems and difficulties in clinical application remain. This review presents a comprehensive analysis of cancer\/testis antigens in digestive tract cancers, covering their expression, function, and potential as an immunotherapy target. Additionally, the current state of cancer\/testis antigens in digestive tract cancer immunotherapy is discussed, and we predict that these antigens hold great promise as an avenue for breakthroughs in the treatment of digestive tract cancers.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1190883","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T01:07:55Z","timestamp":1686877675000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Cancer\/testis antigens: promising immunotherapy targets for digestive tract cancers"],"prefix":"10.3389","volume":"14","author":[{"given":"Huihan","family":"Ai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41568-022-00544-4","article-title":"Mechanisms driving the immunoregulatory function of cancer cells","volume":"23","author":"van Weverwijk","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/270515a0","article-title":"Isolation of a human teratoma cell line which expresses F9 antigen","volume":"270","author":"Hogan","year":"1977","journal-title":"NATURE"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/270518a0","article-title":"Human and mouse embryonal carcinoma cells in culture share an embryonic antigen (F9)","volume":"270","author":"Holden","year":"1977","journal-title":"NATURE"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.22034\/APJCP.2018.19.2.463","article-title":"AKAP4, SPAG9 and NY-ESO-1 in Iranian colorectal cancer patients as probable diagnostic and prognostic biomarkers","volume":"19","author":"Tavakoli","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcancer.2018.08.006","article-title":"Cancer-testis antigens: unique cancer stem cell biomarkers and targets for cancer therapy","volume":"53","author":"Gordeeva","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2006-0469","article-title":"Concise review: cancer\/testis antigens, stem cells, and cancer","volume":"25","author":"Costa","year":"2007","journal-title":"Stem Cells"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.04.168","article-title":"Emerging role of sperm-associated antigen 9 in tumorigenesis","volume":"103","author":"Pan","year":"2018","journal-title":"BioMed Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.03.509","article-title":"NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer","volume":"145","author":"Szender","year":"2017","journal-title":"GYNECOL Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12885-018-4000-y","article-title":"Testes-specific protease 50 (TSP50) promotes invasion and metastasis by inducing EMT in gastric cancer","volume":"18","author":"Cao","year":"2018","journal-title":"BMC Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/ijms20010051","article-title":"Role of HDAC3-miRNA-CAGE network in anti-cancer drug-resistance","volume":"20","author":"Kwon","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.25.11810","article-title":"Human neoplasms elicit multiple specific immune responses in the autologous host","volume":"92","author":"Sahin","year":"1995","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.5.1914","article-title":"A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening","volume":"94","author":"Chen","year":"1997","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000134734","article-title":"Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28","volume":"79","author":"Chen","year":"1997","journal-title":"Cytogenet Cell Genet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.9.5211","article-title":"Identification of a meiosis-specific protein as a member of the class of cancer\/testis antigens","volume":"95","author":"T\u00fcreci","year":"1998","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.8.1163","article-title":"New paths in human cancer serology","volume":"187","author":"Old","year":"1998","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"10499","DOI":"10.1038\/ncomms10499","article-title":"Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types","volume":"7","author":"Wang","year":"2016","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4161\/cc.29661","article-title":"Cancer germline gene activation: friend or foe","volume":"13","author":"McFarlane","year":"2014","journal-title":"Cell Cycle"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810777105","article-title":"Genome-wide analysis of cancer\/testis gene expression","volume":"105","author":"Hofmann","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910630411","article-title":"Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes","volume":"63","author":"Inoue","year":"1995","journal-title":"Int J Cancer"},{"key":"B22","article-title":"Expression of MAGE-a cancer\/testis antigens in esophageal squamous cell carcinomas","volume":"26","author":"Haier","year":"2006","journal-title":"Anticancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21219","article-title":"Heterogeneous expression of GAGE, NY-ESO-1, MAGE-a and SSX proteins in esophageal cancer: implications for immunotherapy","volume":"118","author":"Akcakanat","year":"2006","journal-title":"Int J Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ctrv.2018.04.009","article-title":"MAGE-a antigens as targets for cancer immunotherapy","volume":"67","author":"Schooten","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.12.3.15949","article-title":"Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker and potential targets for immunotherapy","volume":"12","author":"Forghanifard","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6614","article-title":"High expression of MAGE-A9 is associated with unfavorable survival in esophageal squamous cell carcinoma","volume":"14","author":"Qi","year":"2017","journal-title":"Oncol Lett"},{"key":"B27","doi-asserted-by":"publisher","first-page":"108632","DOI":"10.1016\/j.biopha.2019.108632","article-title":"Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma","volume":"112","author":"Shi","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B28","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/carcin\/bgaa057","article-title":"Epigenetic modulation combined with PD-1\/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma","volume":"41","author":"Wu","year":"2020","journal-title":"Carcinogenesis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010515)91:10<1882::AID-CNCR1210>3.0.CO;2-H","article-title":"MAGE, BAGE, and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia","volume":"91","author":"D AZP","year":"2015","journal-title":"CANCER-AM Cancer Soc"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/BF02912440","article-title":"Tumor antigens recognized by T lymphocytes","volume":"27","author":"Eynde","year":"1997","journal-title":"Int J Clin Lab Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-04-0819","article-title":"NY-ESO-1 expression and immunogenicity in esophageal cancer","volume":"10","author":"Fujita","year":"2004","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02840-3","article-title":"Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy","volume":"145","author":"Zhang","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02355.x","article-title":"Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer","volume":"103","author":"Okabayashi","year":"2012","journal-title":"Cancer Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210218","article-title":"Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells","volume":"26","author":"Kang","year":"2007","journal-title":"Oncogene"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0858","article-title":"Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes","volume":"65","author":"Vatolin","year":"2005","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2014.03.011","article-title":"Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors","volume":"40","author":"Ghadban","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2017.05.007","article-title":"MAGE-a family is involved in gastric cancer progression and indicates poor prognosis of gastric cancer patients","volume":"213","author":"Lian","year":"2017","journal-title":"Pathol Res Pract"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3892\/or.18.2.329","article-title":"Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer","volume":"18","author":"Suzuki","year":"2007","journal-title":"Oncol Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12029-018-0183-3","article-title":"MAEL cancer-testis antigen as a diagnostic marker in primary stages of gastric cancer with helicobacter pylori infection","volume":"51","author":"Abbaszadegan","year":"2020","journal-title":"J Gastrointest Cancer"},{"key":"B40","article-title":"Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer","volume":"59","author":"Yuan","year":"1999","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"498246","DOI":"10.1155\/2014\/498246","article-title":"Overexpression of testes-specific protease 50 (TSP50) predicts poor prognosis in patients with gastric cancer","volume":"2014","author":"Liu","year":"2014","journal-title":"Gastroenterol Res Pract"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/biot.200800144","article-title":"Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in south African populations","volume":"3","author":"Dakshinamurthy","year":"2008","journal-title":"Biotechnol J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.0.CO;2-N","article-title":"Expression of MAGE-antigens in normal tissues and cancer","volume":"85","author":"Jungbluth","year":"2000","journal-title":"Int J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1365","article-title":"Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue","volume":"11","author":"Li","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21580","article-title":"Differential gene expression profile of MAGE family in taiwanese patients with colorectal cancer","volume":"102","author":"Chung","year":"2010","journal-title":"J Surg Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3892\/or.2011.1521","article-title":"Novel gene hBiot2 is an independent prognostic factor in colorectal cancer patients","volume":"27","author":"Shen","year":"2012","journal-title":"Oncol Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bbrc.2011.02.077","article-title":"Identification of BCP-20 (FBXO39) as a cancer\/testis antigen from colon cancer patients by SEREX","volume":"408","author":"Song","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/s12885-016-2592-7","article-title":"Heat shock protein 70-2 (HSP70-2) is a novel therapeutic target for colorectal cancer and is associated with tumor growth","volume":"16","author":"Jagadish","year":"2016","journal-title":"BMC Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3892\/or.12.2.275","article-title":"Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers","volume":"12","author":"Yuki","year":"2004","journal-title":"Oncol Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.03.030","article-title":"Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities","volume":"177","author":"Vasaikar","year":"2019","journal-title":"CELL"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1139\/o04-056","article-title":"BJ-HCC-20, a potential novel cancer-testis antigen","volume":"82","author":"Dong","year":"2004","journal-title":"Biochem Cell Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2741\/4877","article-title":"PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells","volume":"25","author":"Li","year":"2020","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1471-2407-13-144","article-title":"Derepression of Cancer\/Testis antigens in cancer is associated with distinct patterns of DNA hypomethylation","volume":"13","author":"Kim","year":"2013","journal-title":"BMC Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.prp.2017.05.007","article-title":"MAGE-a family is involved in gastric cancer progression and indicates poor prognosis of gastric cancer patients","volume":"213","author":"Lian","year":"2017","journal-title":"Pathol - Res Pract"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25836","article-title":"Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors","volume":"128","author":"Perez","year":"2011","journal-title":"Int J Cancer"},{"key":"B56","article-title":"Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target","volume":"7","author":"Zhang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2015.08.005","article-title":"Prognostic value of MAGE-A9 expression in patients with colorectal cancer","volume":"40","author":"Zhan","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3892\/or.2011.1521","article-title":"Novel gene hBiot2 is an independent prognostic factor in colorectal cancer patients","volume":"27","author":"Sun","year":"2012","journal-title":"Oncol Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00194.x","article-title":"Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray","volume":"97","author":"Suda","year":"2006","journal-title":"Cancer Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3727\/096504014X14146137738583","article-title":"RNA Interference of Biot2 induces G1 phase arrest and apoptosis in mouse colorectal cancer cell line","volume":"22","author":"Zhou","year":"2015","journal-title":"Oncol Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.02.081","article-title":"Identification and functional analysis of variants of a cancer\/testis antigen LEMD1 in colorectal cancer stem-like cells","volume":"485","author":"Takeda","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B62","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41419-019-1537-x","article-title":"Cancer testis antigen 55 deficiency attenuates colitis-associated colorectal cancer by inhibiting NF-\u03baB signaling","volume":"10","author":"Zhao","year":"2019","journal-title":"Cell Death Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1512329","article-title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic maraba virus currently in first-in-human trials","volume":"8","author":"Pol","year":"2019","journal-title":"ONCOIMMUNOLOGY"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2147\/OV.S154494","article-title":"Development and applications of oncolytic maraba virus vaccines","volume":"7","author":"Pol","year":"2018","journal-title":"Oncolytic Virother"},{"key":"B66","doi-asserted-by":"publisher","first-page":"188558","DOI":"10.1016\/j.bbcan.2021.188558","article-title":"Oncogenic cancer\/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy","volume":"1876","author":"Yang","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B67","first-page":"16","article-title":"LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer","volume":"7","author":"Bender","year":"2007","journal-title":"Cancer Immun A J Acad Cancer Immunol"},{"key":"B68","article-title":"Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1","volume":"54","author":"Harada","year":"2008","journal-title":"Kobe J Med Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23810","article-title":"Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination","volume":"123","author":"Wada","year":"2008","journal-title":"Int J Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/1479-5876-11-246","article-title":"Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients","volume":"11","author":"Kageyama","year":"2013","journal-title":"J Transl Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci Transl Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1200\/JCO.2023.41.4_suppl.147","article-title":"Phase ib open-label study to evaluate safety, tolerability, immunogenicity, and efficacy of multiple subcutaneous injections of PolyPEPI1018 vaccine as an add-on immunotherapy to TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC; OBERTO-201)","volume":"41","author":"Hubbard","year":"2023","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01200.x","article-title":"Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer","volume":"100","author":"Kono","year":"2009","journal-title":"Cancer Sci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"101410","DOI":"10.1016\/j.smim.2020.101410","article-title":"Dendritic cells in the tumor microenvironment: prognostic and theranostic impact","volume":"48","author":"Verneau","year":"2020","journal-title":"Semin Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2011.05.007","article-title":"Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma","volume":"270","author":"Mkrtichyan","year":"2011","journal-title":"Cell Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3109\/02841860903099964","article-title":"Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination","volume":"48","author":"Burgdorf","year":"2009","journal-title":"Acta Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000145","article-title":"Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine","volume":"20","author":"Burgdorf","year":"2008","journal-title":"Oncol Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003218","article-title":"Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy","volume":"9","author":"McAuliffe","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.001","article-title":"Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1","volume":"90","author":"Haag","year":"2018","journal-title":"Eur J Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01568","article-title":"CAR T-cell cancer therapy targeting surface Cancer\/Testis antigens","volume":"11","author":"Jakobsen","year":"2020","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-019-0793-7","article-title":"MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells","volume":"12","author":"Mao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0073","article-title":"Validation of immunogenic PASD1 peptides against HLA-A*24:02 colorectal cancer","volume":"11","author":"Soh","year":"2019","journal-title":"Immunotherapy-UK"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3359","article-title":"High-throughput identification of antigen-specific TCRs by TCR gene capture","volume":"19","author":"Linnemann","year":"2013","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-005-0053-2","article-title":"A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells","volume":"55","author":"Ottaviani","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1559","article-title":"Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer","volume":"21","author":"Kageyama","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1682381","DOI":"10.1080\/2162402X.2019.1682381","article-title":"Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy","volume":"9","author":"Sanderson","year":"2020","journal-title":"ONCOIMMUNOLOGY"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1062","article-title":"540P safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8\u03b1 co-receptor and an affinity optimized TCR targeting MAGE-A4","volume":"32","author":"Hong","year":"2021","journal-title":"Ann Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS363","article-title":"SURPASS-2 trial design: a phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers","volume":"40","author":"Hong","year":"2022","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00018","article-title":"MAGE-a antigens and cancer immunotherapy","volume":"4","author":"Zajac","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1251","article-title":"NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens","volume":"83","author":"Schultz-Thater","year":"2000","journal-title":"Br J Cancer"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1172\/JCI96860","article-title":"A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide\/HLA-I antigens","volume":"127","author":"Chang","year":"2017","journal-title":"J Clin Invest"},{"key":"B96","doi-asserted-by":"publisher","first-page":"13293","DOI":"10.1038\/s41598-019-49834-2","article-title":"Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy","volume":"9","author":"Maruta","year":"2019","journal-title":"Sci Rep"},{"key":"B97","doi-asserted-by":"publisher","first-page":"215699","DOI":"10.1016\/j.canlet.2022.215699","article-title":"Therapeutic bispecific antibodies against intracellular tumor antigens","volume":"538","author":"Xu","year":"2022","journal-title":"Cancer Lett"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19579","article-title":"In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)","volume":"8","author":"Pankov","year":"2017","journal-title":"Oncotarget"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29375","article-title":"Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype","volume":"138","author":"Garrido","year":"2016","journal-title":"Int J Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/nature12433","article-title":"Charting a dynamic DNA methylation landscape of the human genome","volume":"500","author":"Ziller","year":"2013","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31824300c7","article-title":"Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer","volume":"35","author":"Chou","year":"2012","journal-title":"J Immunother"},{"key":"B103","first-page":"9","article-title":"Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine","volume":"9","author":"Weinert","year":"2009","journal-title":"Cancer Immun"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0669","article-title":"Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura","volume":"12","author":"Schrump","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179501","article-title":"Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells","volume":"12","author":"Siebenkas","year":"2017","journal-title":"PloS One"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1116","article-title":"Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity","volume":"18","author":"Karbach","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1656-x","article-title":"Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1\/ISCOMATRIX vaccine in patients with advanced melanoma","volume":"64","author":"Klein","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139221","article-title":"Treatment with 5-Aza-2'-Deoxycytidine induces expression of NY-ESO-1 and facilitates cytotoxic T lymphocyte-mediated tumor cell killing","volume":"10","author":"Klar","year":"2015","journal-title":"PloS One"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136368","article-title":"Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer","volume":"5","author":"Kim","year":"2020","journal-title":"JCI Insight"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1190883\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T01:08:05Z","timestamp":1686877685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1190883\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":109,"alternative-id":["10.3389\/fimmu.2023.1190883"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1190883","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"article-number":"1190883"}}